stockrow
Saturday 7 November 2026
Export IPSC’s income statement to Excel — free account
Century Therapeutics, Inc.
IPSC Healthcare Biotechnology
Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024.
- Revenue
- +12,667.7%
- EPS
- +55.3%
- Free cash flow
- +26.7%
Quarter to June 2026, against a year earlier
1.68
0.17
+11.26%
Follow IPSC
Alert me
Century Therapeutics, Inc. (IPSC) P/E ratio
Century Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. | n/m |
| VOGX Vogenx Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)